A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog

Trial Profile

A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Adocia
  • Most Recent Events

    • 16 Dec 2016 Primary endpoint has been met. (Pharmacodynamics: AUCBG 0-2h), as reported in an Eli Lilly media release.
    • 16 Dec 2016 Results published in the an Eli Lilly Media Release
    • 16 Dec 2016 Primary endpoint has been met. (Pharmacokinetics: AUClis 0-30min), as reported in an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top